201 related articles for article (PubMed ID: 21042777)
21. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
[TBL] [Abstract][Full Text] [Related]
22. Oestrogen receptor/progesterone receptor and human epidermal growth factor receptor 2 status in breast cancer: a 9-year study at Princess Noorah Oncology Center, Saudi Arabia.
Satti MB
Histopathology; 2011 Sep; 59(3):537-42. PubMed ID: 21668473
[TBL] [Abstract][Full Text] [Related]
23. Comparison of central laboratory assessments of ER, PR, HER2, and Ki67 by IHC/FISH and the corresponding mRNAs (ESR1, PGR, ERBB2, and MKi67) by RT-qPCR on an automated, broadly deployed diagnostic platform.
Wu NC; Wong W; Ho KE; Chu VC; Rizo A; Davenport S; Kelly D; Makar R; Jassem J; Duchnowska R; Biernat W; Radecka B; Fujita T; Klein JL; Stonecypher M; Ohta S; Juhl H; Weidler JM; Bates M; Press MF
Breast Cancer Res Treat; 2018 Nov; 172(2):327-338. PubMed ID: 30120700
[TBL] [Abstract][Full Text] [Related]
24. Correlations between HER2 Expression and Other Prognostic Factors in Breast Cancer: Inverse Relations with the Ki-67 Index and P53 Status.
Payandeh M; Shahriari-Ahmadi A; Sadeghi M; Sadeghi E
Asian Pac J Cancer Prev; 2016; 17(3):1015-8. PubMed ID: 27039719
[TBL] [Abstract][Full Text] [Related]
25. Prognostic utility of fluorescence in situ hybridization for determining HER2 gene amplification in breast cancer.
Kammori M; Kurabayashi R; Kashio M; Sakamoto A; Yoshimoto M; Amano S; Kaminishi M; Yamada T; Takubo K
Oncol Rep; 2008 Mar; 19(3):651-6. PubMed ID: 18288397
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of HER2 gene amplification detected by chromogenic in situ hybridization (CISH) in metastatic breast cancer.
Todorović-Raković N; Jovanović D; Nesković-Konstantinović Z; Nikolić-Vukosavljević D
Exp Mol Pathol; 2007 Jun; 82(3):262-8. PubMed ID: 17335803
[TBL] [Abstract][Full Text] [Related]
27. Expression and amplification of Her2, EGFR and cyclin D1 in breast cancer: immunohistochemistry and chromogenic in situ hybridization.
Cho EY; Choi YL; Han JJ; Kim KM; Oh YL
Pathol Int; 2008 Jan; 58(1):17-25. PubMed ID: 18067636
[TBL] [Abstract][Full Text] [Related]
28. Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.
Skarlos P; Christodoulou C; Kalogeras KT; Eleftheraki AG; Bobos M; Batistatou A; Valavanis C; Tzaida O; Timotheadou E; Kronenwett R; Wirtz RM; Kostopoulos I; Televantou D; Koutselini E; Papaspirou I; Papadimitriou CA; Pectasides D; Gogas H; Aravantinos G; Pavlidis N; Arapantoni P; Skarlos DV; Fountzilas G
Cancer Chemother Pharmacol; 2012 Feb; 69(2):533-46. PubMed ID: 21901395
[TBL] [Abstract][Full Text] [Related]
29. Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up.
Rydén L; Jirström K; Haglund M; Stål O; Fernö M
Breast Cancer Res Treat; 2010 Apr; 120(2):491-8. PubMed ID: 20135347
[TBL] [Abstract][Full Text] [Related]
30. The multigene signature MammaPrint impacts on multidisciplinary team decisions in ER+, HER2- early breast cancer.
Exner R; Bago-Horvath Z; Bartsch R; Mittlboeck M; Retèl VP; Fitzal F; Rudas M; Singer C; Pfeiler G; Gnant M; Jakesz R; Dubsky P
Br J Cancer; 2014 Aug; 111(5):837-42. PubMed ID: 25003667
[TBL] [Abstract][Full Text] [Related]
31. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
32. Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors.
Brouckaert O; Pintens S; Van Belle V; Van Huffel S; Camerlynck E; Amant F; Leunen K; Smeets A; Berteloot P; Van Limbergen E; Decock J; Hendrickx W; Weltens C; Van den Bogaert W; Vanden Bempt I; Drijkoningen M; Paridaens R; Wildiers H; Vergote I; Christiaens MR; Neven P
Breast Cancer Res Treat; 2009 May; 115(2):349-58. PubMed ID: 18629635
[TBL] [Abstract][Full Text] [Related]
33. Assessing the impact of polysomy-17 on HER2 status and the correlations of HER2 status with prognostic variables (ER, PR, p53, Ki-67) in epithelial ovarian cancer: a tissue microarray study using immunohistochemistry and fluorescent in situ hybridization.
Lin CK; Lin WL; Chen FL; Lee MY; Kuo JF; Ruan A; Tyan YS; Chiang H; Chou MC; Han CP
Int J Gynecol Pathol; 2011 Jul; 30(4):372-9. PubMed ID: 21623202
[TBL] [Abstract][Full Text] [Related]
34. The multigene classifiers 95GC/42GC/155GC for precision medicine in ER-positive HER2-negative early breast cancer.
Naoi Y; Tsunashima R; Shimazu K; Noguchi S
Cancer Sci; 2021 Apr; 112(4):1369-1375. PubMed ID: 33544932
[TBL] [Abstract][Full Text] [Related]
35. ESR1, PGR, ERBB2, and MKi67 mRNA expression in postmenopausal women with hormone receptor-positive early breast cancer: results from ABCSG Trial 6.
Filipits M; Rudas M; Singer CF; Fitzal F; Bago-Horvath Z; Greil R; Balic M; Lax SF; Halper S; Hulla W; Wu NC; Liu X; Weidler J; Bates M; Hlauschek D; Gnant M; Dubsky P
ESMO Open; 2021 Aug; 6(4):100228. PubMed ID: 34371382
[TBL] [Abstract][Full Text] [Related]
36. The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study.
Borgquist S; Zhou W; Jirström K; Amini RM; Sollie T; Sørlie T; Blomqvist C; Butt S; Wärnberg F
BMC Cancer; 2015 Jun; 15():468. PubMed ID: 26062614
[TBL] [Abstract][Full Text] [Related]
37. Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study.
Wuerstlein R; Kates R; Gluz O; Grischke EM; Schem C; Thill M; Hasmueller S; Köhler A; Otremba B; Griesinger F; Schindlbeck C; Trojan A; Otto F; Knauer M; Pusch R; Harbeck N;
Breast Cancer Res Treat; 2019 Jun; 175(2):389-399. PubMed ID: 30796651
[TBL] [Abstract][Full Text] [Related]
38. Metastatic breast carcinoma in pleural fluid: Correlation of receptor and HER2 status with the primary carcinoma-a pilot study.
Francis IM; Alath P; George SS; Jaragh M; Al Jassar A; Kapila K
Diagn Cytopathol; 2016 Dec; 44(12):980-986. PubMed ID: 27666130
[TBL] [Abstract][Full Text] [Related]
39. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
[TBL] [Abstract][Full Text] [Related]
40. Predictive markers in breast cancer: An update on ER and HER2 testing and reporting.
Calhoun BC; Collins LC
Semin Diagn Pathol; 2015 Sep; 32(5):362-9. PubMed ID: 25770732
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]